John Corboy
Concepts (369)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Sclerosis | 47 | 2024 | 380 | 8.350 |
Why?
| Multiple Sclerosis, Relapsing-Remitting | 14 | 2024 | 69 | 3.130 |
Why?
| Neurology | 10 | 2018 | 85 | 2.510 |
Why?
| Immunosuppressive Agents | 10 | 2024 | 666 | 1.820 |
Why?
| Immunologic Factors | 11 | 2020 | 219 | 1.720 |
Why?
| Neuromyelitis Optica | 4 | 2023 | 114 | 1.260 |
Why?
| Natalizumab | 11 | 2021 | 46 | 1.020 |
Why?
| Recurrence | 7 | 2024 | 949 | 0.800 |
Why?
| Diagnostic Errors | 2 | 2017 | 151 | 0.780 |
Why?
| Internship and Residency | 5 | 2011 | 949 | 0.760 |
Why?
| Drug Substitution | 2 | 2019 | 46 | 0.700 |
Why?
| Fingolimod Hydrochloride | 5 | 2020 | 30 | 0.690 |
Why?
| Rituximab | 4 | 2020 | 149 | 0.660 |
Why?
| Brain | 14 | 2021 | 2382 | 0.650 |
Why?
| Data Collection | 4 | 2011 | 636 | 0.640 |
Why?
| Dementia, Vascular | 3 | 2009 | 17 | 0.630 |
Why?
| Drug Monitoring | 1 | 2019 | 184 | 0.610 |
Why?
| Early Medical Intervention | 1 | 2017 | 51 | 0.570 |
Why?
| Medication Adherence | 2 | 2019 | 536 | 0.570 |
Why?
| Early Diagnosis | 2 | 2017 | 221 | 0.560 |
Why?
| Glatiramer Acetate | 6 | 2019 | 20 | 0.540 |
Why?
| Physicians | 4 | 2016 | 774 | 0.540 |
Why?
| Calcinosis | 2 | 2009 | 244 | 0.510 |
Why?
| Antibodies, Monoclonal, Humanized | 8 | 2023 | 664 | 0.510 |
Why?
| Postural Balance | 3 | 2018 | 182 | 0.510 |
Why?
| Humans | 79 | 2024 | 115899 | 0.490 |
Why?
| Magnetic Resonance Imaging | 23 | 2023 | 3086 | 0.470 |
Why?
| Fatigue | 3 | 2018 | 295 | 0.430 |
Why?
| Dimethyl Fumarate | 3 | 2020 | 10 | 0.400 |
Why?
| Immunoglobulin G | 4 | 2023 | 782 | 0.390 |
Why?
| Practice Guidelines as Topic | 1 | 2018 | 1403 | 0.360 |
Why?
| Multiple Sclerosis, Chronic Progressive | 3 | 2020 | 25 | 0.360 |
Why?
| Withholding Treatment | 2 | 2021 | 69 | 0.350 |
Why?
| Middle Aged | 37 | 2021 | 27082 | 0.340 |
Why?
| Psychiatry | 2 | 2009 | 155 | 0.330 |
Why?
| Adult | 41 | 2023 | 30816 | 0.310 |
Why?
| Cysts | 1 | 2009 | 94 | 0.310 |
Why?
| Demyelinating Diseases | 4 | 2019 | 76 | 0.310 |
Why?
| Education, Medical | 1 | 2011 | 224 | 0.310 |
Why?
| Certification | 1 | 2008 | 90 | 0.300 |
Why?
| Autoantibodies | 3 | 2023 | 1362 | 0.300 |
Why?
| Clinical Trials as Topic | 3 | 2016 | 945 | 0.290 |
Why?
| Education | 2 | 2007 | 99 | 0.280 |
Why?
| Central Nervous System Cysts | 1 | 2006 | 12 | 0.280 |
Why?
| Cerebral Arteries | 1 | 2006 | 55 | 0.270 |
Why?
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2023 | 43 | 0.270 |
Why?
| Single-Blind Method | 3 | 2023 | 256 | 0.270 |
Why?
| Cerebrovascular Disorders | 1 | 2006 | 82 | 0.270 |
Why?
| Societies, Medical | 4 | 2019 | 690 | 0.260 |
Why?
| Treatment Outcome | 12 | 2023 | 9165 | 0.260 |
Why?
| HIV Long Terminal Repeat | 2 | 1997 | 7 | 0.260 |
Why?
| DNA, Viral | 2 | 1998 | 351 | 0.260 |
Why?
| Female | 46 | 2023 | 60080 | 0.260 |
Why?
| Databases, Factual | 3 | 2016 | 1149 | 0.250 |
Why?
| Double-Blind Method | 4 | 2023 | 1665 | 0.240 |
Why?
| Male | 36 | 2023 | 56125 | 0.240 |
Why?
| Drug Industry | 2 | 2016 | 104 | 0.240 |
Why?
| Conflict of Interest | 2 | 2016 | 120 | 0.230 |
Why?
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2023 | 50 | 0.220 |
Why?
| Quality of Health Care | 2 | 2017 | 578 | 0.200 |
Why?
| B-Lymphocytes | 5 | 2023 | 770 | 0.200 |
Why?
| Mental Disorders | 2 | 2007 | 908 | 0.200 |
Why?
| Brain Neoplasms | 4 | 2016 | 979 | 0.200 |
Why?
| Lymphoma | 2 | 2005 | 177 | 0.200 |
Why?
| Interferon beta-1a | 2 | 2019 | 12 | 0.190 |
Why?
| Central Nervous System Neoplasms | 2 | 2005 | 125 | 0.190 |
Why?
| Neuroimaging | 1 | 2023 | 251 | 0.190 |
Why?
| Education, Medical, Continuing | 2 | 2015 | 119 | 0.190 |
Why?
| Lymphopenia | 1 | 2020 | 49 | 0.180 |
Why?
| Disease Progression | 4 | 2021 | 2424 | 0.180 |
Why?
| Agammaglobulinemia | 1 | 2020 | 31 | 0.180 |
Why?
| Referral and Consultation | 1 | 2005 | 647 | 0.180 |
Why?
| Interferon-gamma | 1 | 2023 | 731 | 0.180 |
Why?
| Neutropenia | 1 | 2020 | 127 | 0.170 |
Why?
| Serum Sickness | 1 | 2019 | 7 | 0.170 |
Why?
| Indans | 1 | 2019 | 9 | 0.170 |
Why?
| Oxadiazoles | 1 | 2019 | 32 | 0.170 |
Why?
| Diagnosis, Differential | 4 | 2023 | 1358 | 0.170 |
Why?
| Adjuvants, Immunologic | 3 | 2015 | 205 | 0.160 |
Why?
| Educational Measurement | 3 | 2015 | 264 | 0.160 |
Why?
| Lymphoma, AIDS-Related | 1 | 1998 | 13 | 0.150 |
Why?
| Salvage Therapy | 1 | 2019 | 128 | 0.150 |
Why?
| Physician-Patient Relations | 2 | 2016 | 466 | 0.150 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 522 | 0.150 |
Why?
| Eye Movements | 1 | 2018 | 53 | 0.150 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 242 | 0.150 |
Why?
| Herpesvirus 8, Human | 1 | 1998 | 63 | 0.150 |
Why?
| AIDS Dementia Complex | 1 | 1997 | 50 | 0.150 |
Why?
| Diffuse Cerebral Sclerosis of Schilder | 1 | 2017 | 4 | 0.150 |
Why?
| Central Nervous System | 2 | 2005 | 239 | 0.150 |
Why?
| Patient Selection | 2 | 2015 | 656 | 0.150 |
Why?
| Sarcoma, Kaposi | 1 | 1998 | 69 | 0.150 |
Why?
| Herpesvirus 4, Human | 1 | 2018 | 123 | 0.150 |
Why?
| HIV Seropositivity | 1 | 1998 | 110 | 0.140 |
Why?
| Young Adult | 6 | 2023 | 10516 | 0.140 |
Why?
| Neurologists | 1 | 2016 | 18 | 0.140 |
Why?
| Herpesviridae Infections | 1 | 1998 | 138 | 0.140 |
Why?
| Costs and Cost Analysis | 1 | 2017 | 200 | 0.140 |
Why?
| Cost-Benefit Analysis | 2 | 2016 | 545 | 0.140 |
Why?
| Aged | 8 | 2023 | 19298 | 0.130 |
Why?
| Estriol | 1 | 2015 | 5 | 0.130 |
Why?
| T-Lymphocytes | 1 | 2023 | 1754 | 0.130 |
Why?
| Dizziness | 2 | 2018 | 70 | 0.130 |
Why?
| Verbal Learning | 2 | 2013 | 63 | 0.130 |
Why?
| Corpus Callosum | 2 | 2006 | 57 | 0.130 |
Why?
| Follow-Up Studies | 6 | 2020 | 4446 | 0.130 |
Why?
| Diffusion Magnetic Resonance Imaging | 2 | 2006 | 86 | 0.130 |
Why?
| Trust | 1 | 2016 | 108 | 0.120 |
Why?
| Retrospective Studies | 9 | 2020 | 12616 | 0.120 |
Why?
| Ethics, Medical | 1 | 2015 | 70 | 0.120 |
Why?
| Mesenchymal Stem Cell Transplantation | 1 | 2014 | 37 | 0.120 |
Why?
| Exercise Therapy | 1 | 2018 | 353 | 0.120 |
Why?
| Insurance, Health | 1 | 2016 | 247 | 0.110 |
Why?
| Medication Reconciliation | 1 | 2013 | 25 | 0.110 |
Why?
| CD40 Antigens | 1 | 2014 | 80 | 0.110 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2014 | 129 | 0.110 |
Why?
| JC Virus | 1 | 2013 | 23 | 0.110 |
Why?
| Anti-Inflammatory Agents | 2 | 2006 | 447 | 0.110 |
Why?
| Population Surveillance | 1 | 2016 | 397 | 0.110 |
Why?
| Sensation Disorders | 1 | 2012 | 30 | 0.110 |
Why?
| Glioma | 1 | 2016 | 296 | 0.100 |
Why?
| Memory Disorders | 1 | 2013 | 155 | 0.100 |
Why?
| Immune Reconstitution Inflammatory Syndrome | 1 | 2012 | 18 | 0.100 |
Why?
| Immunoglobulin Heavy Chains | 3 | 2007 | 72 | 0.100 |
Why?
| Leukoencephalopathy, Progressive Multifocal | 1 | 2012 | 38 | 0.100 |
Why?
| Lymphoma, T-Cell, Peripheral | 1 | 2012 | 15 | 0.100 |
Why?
| Optic Nerve | 2 | 2005 | 65 | 0.100 |
Why?
| T-Lymphocyte Subsets | 1 | 2014 | 382 | 0.100 |
Why?
| Gadolinium | 4 | 2018 | 78 | 0.090 |
Why?
| Quality of Life | 3 | 2021 | 2392 | 0.090 |
Why?
| Learning | 1 | 2015 | 360 | 0.090 |
Why?
| Self-Assessment | 1 | 2011 | 63 | 0.090 |
Why?
| Academies and Institutes | 1 | 2011 | 44 | 0.090 |
Why?
| Biomarkers | 3 | 2014 | 3473 | 0.090 |
Why?
| Nervous System Diseases | 1 | 2013 | 253 | 0.090 |
Why?
| Nerve Regeneration | 1 | 2010 | 53 | 0.090 |
Why?
| Fatal Outcome | 3 | 2006 | 286 | 0.090 |
Why?
| Diagnostic Tests, Routine | 1 | 2011 | 89 | 0.090 |
Why?
| Antigens, CD19 | 3 | 2007 | 97 | 0.090 |
Why?
| Leukocytosis | 1 | 2010 | 35 | 0.090 |
Why?
| Exercise Test | 1 | 2012 | 541 | 0.090 |
Why?
| Severity of Illness Index | 3 | 2014 | 2598 | 0.090 |
Why?
| Cranial Nerve Neoplasms | 1 | 1989 | 6 | 0.090 |
Why?
| Hemangioma, Cavernous | 1 | 1989 | 15 | 0.090 |
Why?
| Optic Chiasm | 1 | 1989 | 18 | 0.090 |
Why?
| Central Nervous System Infections | 1 | 2010 | 36 | 0.090 |
Why?
| Disease Management | 1 | 2013 | 562 | 0.080 |
Why?
| United States | 7 | 2019 | 12340 | 0.080 |
Why?
| Guidelines as Topic | 1 | 2011 | 246 | 0.080 |
Why?
| Spinal Cord | 3 | 2023 | 351 | 0.080 |
Why?
| Neuroprotective Agents | 1 | 2009 | 105 | 0.080 |
Why?
| Physical Therapy Modalities | 1 | 2011 | 270 | 0.080 |
Why?
| Practice Patterns, Physicians' | 1 | 2016 | 1177 | 0.080 |
Why?
| Workload | 1 | 2009 | 132 | 0.080 |
Why?
| Hospital-Physician Relations | 1 | 2007 | 2 | 0.070 |
Why?
| Antibodies, Monoclonal | 2 | 2011 | 1262 | 0.070 |
Why?
| Neuropsychological Tests | 2 | 2013 | 932 | 0.070 |
Why?
| Immunoglobulin Variable Region | 2 | 2004 | 72 | 0.070 |
Why?
| HIV-1 | 1 | 1992 | 769 | 0.070 |
Why?
| Headache Disorders | 1 | 2006 | 12 | 0.070 |
Why?
| Vasculitis, Central Nervous System | 1 | 2006 | 17 | 0.070 |
Why?
| Nerve Fibers, Myelinated | 1 | 2006 | 41 | 0.070 |
Why?
| Huntington Disease | 1 | 2007 | 38 | 0.070 |
Why?
| Medical Records | 1 | 2007 | 157 | 0.070 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2006 | 82 | 0.070 |
Why?
| Syndrome | 2 | 2023 | 339 | 0.070 |
Why?
| International Classification of Diseases | 1 | 2007 | 118 | 0.070 |
Why?
| Methylprednisolone | 1 | 2006 | 83 | 0.070 |
Why?
| Contrast Media | 3 | 2018 | 366 | 0.070 |
Why?
| Antibody Formation | 1 | 2007 | 273 | 0.070 |
Why?
| Intracranial Hemorrhages | 1 | 2006 | 76 | 0.070 |
Why?
| Aquaporin 4 | 1 | 2006 | 86 | 0.070 |
Why?
| Fellowships and Scholarships | 1 | 2009 | 240 | 0.070 |
Why?
| Herpes Zoster | 1 | 2010 | 333 | 0.070 |
Why?
| Canada | 2 | 2019 | 337 | 0.070 |
Why?
| Surveys and Questionnaires | 4 | 2016 | 4671 | 0.060 |
Why?
| DNA Mutational Analysis | 1 | 2006 | 378 | 0.060 |
Why?
| RNA, Messenger | 1 | 1992 | 2581 | 0.060 |
Why?
| Health Care Surveys | 1 | 2007 | 540 | 0.060 |
Why?
| Patient Compliance | 1 | 2009 | 524 | 0.060 |
Why?
| Erythrocytes | 1 | 2010 | 590 | 0.060 |
Why?
| Cognition Disorders | 1 | 2009 | 479 | 0.060 |
Why?
| Teaching | 1 | 2007 | 226 | 0.060 |
Why?
| Affect | 1 | 2007 | 244 | 0.060 |
Why?
| Neurologic Examination | 1 | 2005 | 117 | 0.060 |
Why?
| Analysis of Variance | 3 | 2015 | 1226 | 0.060 |
Why?
| Program Evaluation | 1 | 2009 | 839 | 0.060 |
Why?
| Central Nervous System Diseases | 1 | 2005 | 62 | 0.060 |
Why?
| Neutrophils | 1 | 2010 | 1170 | 0.060 |
Why?
| Simvastatin | 1 | 2004 | 60 | 0.060 |
Why?
| Faculty, Medical | 1 | 2006 | 233 | 0.060 |
Why?
| Ophthalmoplegia | 1 | 2003 | 8 | 0.060 |
Why?
| Proteoglycans | 1 | 2004 | 108 | 0.060 |
Why?
| Diagnostic Techniques, Ophthalmological | 1 | 2003 | 36 | 0.060 |
Why?
| Adolescent | 7 | 2021 | 17955 | 0.050 |
Why?
| B-Lymphocyte Subsets | 1 | 2003 | 67 | 0.050 |
Why?
| Cyclophosphamide | 1 | 2003 | 218 | 0.050 |
Why?
| Anticoagulants | 1 | 2006 | 545 | 0.050 |
Why?
| Radiography | 1 | 2005 | 827 | 0.050 |
Why?
| Cross-Sectional Studies | 1 | 2012 | 4449 | 0.050 |
Why?
| Academic Medical Centers | 1 | 2005 | 415 | 0.050 |
Why?
| Students, Medical | 1 | 2006 | 280 | 0.050 |
Why?
| Dementia | 1 | 2005 | 185 | 0.050 |
Why?
| Membrane Glycoproteins | 1 | 2004 | 429 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2023 | 374 | 0.050 |
Why?
| Lymphoma, B-Cell | 2 | 2005 | 85 | 0.050 |
Why?
| Patient Outcome Assessment | 1 | 2023 | 123 | 0.050 |
Why?
| Clinical Competence | 1 | 2008 | 918 | 0.050 |
Why?
| Peptides | 3 | 2013 | 862 | 0.050 |
Why?
| Time Factors | 4 | 2018 | 6186 | 0.050 |
Why?
| Pain | 1 | 2007 | 713 | 0.050 |
Why?
| Schools, Medical | 1 | 2002 | 125 | 0.050 |
Why?
| Disability Evaluation | 2 | 2014 | 273 | 0.050 |
Why?
| Molecular Sequence Data | 3 | 2004 | 2793 | 0.050 |
Why?
| Antibodies, Antinuclear | 1 | 2001 | 60 | 0.050 |
Why?
| Atrophy | 1 | 2021 | 154 | 0.050 |
Why?
| Consensus | 1 | 2023 | 533 | 0.050 |
Why?
| Child | 5 | 2016 | 18555 | 0.050 |
Why?
| Mobility Limitation | 1 | 2020 | 60 | 0.040 |
Why?
| Antibodies, Viral | 1 | 2023 | 520 | 0.040 |
Why?
| Interferon-beta | 2 | 2011 | 80 | 0.040 |
Why?
| Lymphocyte Activation | 1 | 2003 | 1056 | 0.040 |
Why?
| Lipids | 1 | 2023 | 589 | 0.040 |
Why?
| Maintenance Chemotherapy | 1 | 2019 | 22 | 0.040 |
Why?
| Induction Chemotherapy | 1 | 2019 | 56 | 0.040 |
Why?
| Cerebral Infarction | 1 | 1998 | 39 | 0.040 |
Why?
| Cell Separation | 2 | 2014 | 293 | 0.040 |
Why?
| Transplantation, Autologous | 1 | 2019 | 176 | 0.040 |
Why?
| HIV Seronegativity | 1 | 1998 | 24 | 0.040 |
Why?
| Genes, myc | 1 | 1998 | 47 | 0.040 |
Why?
| Astrocytoma | 1 | 1998 | 108 | 0.040 |
Why?
| Risk Assessment | 1 | 2006 | 3004 | 0.040 |
Why?
| In Situ Hybridization | 1 | 2018 | 298 | 0.040 |
Why?
| Gene Library | 1 | 1997 | 116 | 0.040 |
Why?
| Gene Rearrangement | 1 | 1998 | 135 | 0.040 |
Why?
| Breast Neoplasms | 1 | 2008 | 1870 | 0.040 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 319 | 0.040 |
Why?
| Syndecan-1 | 2 | 2007 | 28 | 0.030 |
Why?
| Flow Cytometry | 2 | 2014 | 1058 | 0.030 |
Why?
| Mutation | 1 | 2006 | 3369 | 0.030 |
Why?
| Viral Load | 1 | 2018 | 406 | 0.030 |
Why?
| Drug Administration Schedule | 1 | 2018 | 724 | 0.030 |
Why?
| Colorado | 1 | 2005 | 4122 | 0.030 |
Why?
| Child, Preschool | 3 | 2016 | 9175 | 0.030 |
Why?
| Polymerase Chain Reaction | 1 | 1998 | 1001 | 0.030 |
Why?
| Survival Analysis | 1 | 2018 | 1221 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 1997 | 733 | 0.030 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 1193 | 0.030 |
Why?
| Patient Care Team | 1 | 2019 | 521 | 0.030 |
Why?
| Incidence | 1 | 2020 | 2333 | 0.030 |
Why?
| Base Sequence | 1 | 1997 | 2120 | 0.030 |
Why?
| Congresses as Topic | 1 | 2015 | 200 | 0.030 |
Why?
| Propylene Glycols | 1 | 2013 | 26 | 0.030 |
Why?
| Ocular Physiological Phenomena | 1 | 1992 | 11 | 0.030 |
Why?
| Sphingosine | 1 | 2013 | 32 | 0.030 |
Why?
| HLA-DR Antigens | 1 | 2014 | 220 | 0.030 |
Why?
| beta-Galactosidase | 1 | 1992 | 63 | 0.030 |
Why?
| Quality-Adjusted Life Years | 1 | 2013 | 103 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2015 | 961 | 0.030 |
Why?
| Markov Chains | 1 | 2013 | 115 | 0.030 |
Why?
| Mice | 2 | 2023 | 15073 | 0.030 |
Why?
| Mice, Inbred DBA | 1 | 1992 | 173 | 0.030 |
Why?
| Animals | 3 | 2023 | 32121 | 0.030 |
Why?
| Haplotypes | 1 | 2014 | 472 | 0.030 |
Why?
| Mental Recall | 1 | 2013 | 173 | 0.030 |
Why?
| Comparative Effectiveness Research | 1 | 2013 | 130 | 0.030 |
Why?
| Organ Specificity | 1 | 1992 | 273 | 0.030 |
Why?
| Reference Values | 1 | 2013 | 745 | 0.030 |
Why?
| CD3 Complex | 1 | 2012 | 92 | 0.030 |
Why?
| Depression | 2 | 2011 | 1149 | 0.030 |
Why?
| Intestine, Small | 1 | 1992 | 125 | 0.020 |
Why?
| Ki-67 Antigen | 1 | 2012 | 104 | 0.020 |
Why?
| Thymus Gland | 1 | 1992 | 297 | 0.020 |
Why?
| Mitoxantrone | 1 | 2011 | 12 | 0.020 |
Why?
| Patient Participation | 1 | 2015 | 362 | 0.020 |
Why?
| Hematologic Tests | 1 | 2011 | 22 | 0.020 |
Why?
| Muscle Stretching Exercises | 1 | 2011 | 17 | 0.020 |
Why?
| Clinical Laboratory Techniques | 1 | 2011 | 86 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2006 | 1216 | 0.020 |
Why?
| Aged, 80 and over | 2 | 2016 | 6438 | 0.020 |
Why?
| Physical Endurance | 1 | 2011 | 223 | 0.020 |
Why?
| Recombinant Fusion Proteins | 1 | 1992 | 616 | 0.020 |
Why?
| Amino Acid Sequence | 2 | 2004 | 2000 | 0.020 |
Why?
| Prevalence | 1 | 2016 | 2271 | 0.020 |
Why?
| Acyclovir | 1 | 2010 | 100 | 0.020 |
Why?
| Spinal Cord Neoplasms | 1 | 1989 | 40 | 0.020 |
Why?
| Respiratory Function Tests | 1 | 2011 | 541 | 0.020 |
Why?
| Cell Count | 1 | 2010 | 304 | 0.020 |
Why?
| History, 19th Century | 1 | 2009 | 57 | 0.020 |
Why?
| Pilot Projects | 2 | 2004 | 1374 | 0.020 |
Why?
| Neoplasms, Multiple Primary | 1 | 1989 | 52 | 0.020 |
Why?
| Injections | 1 | 2009 | 163 | 0.020 |
Why?
| History, 21st Century | 1 | 2009 | 164 | 0.020 |
Why?
| Autoimmunity | 1 | 2014 | 823 | 0.020 |
Why?
| Electrocardiography | 1 | 2011 | 554 | 0.020 |
Why?
| History, 20th Century | 1 | 2009 | 276 | 0.020 |
Why?
| Mice, Transgenic | 1 | 1992 | 1970 | 0.020 |
Why?
| Age of Onset | 1 | 2009 | 455 | 0.020 |
Why?
| Gene Expression | 1 | 1992 | 1442 | 0.020 |
Why?
| Memory | 1 | 2009 | 211 | 0.020 |
Why?
| Walking | 1 | 2011 | 426 | 0.020 |
Why?
| Health | 1 | 2007 | 74 | 0.020 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2012 | 686 | 0.020 |
Why?
| Prognosis | 2 | 2006 | 3342 | 0.020 |
Why?
| Association Learning | 1 | 2007 | 60 | 0.020 |
Why?
| Cerebral Ventricles | 1 | 2006 | 47 | 0.020 |
Why?
| Motor Skills | 1 | 2007 | 80 | 0.020 |
Why?
| Phenotype | 1 | 2014 | 2858 | 0.020 |
Why?
| Hospitalization | 1 | 2015 | 1761 | 0.020 |
Why?
| Herpesvirus 3, Human | 1 | 2010 | 381 | 0.020 |
Why?
| Immunologic Memory | 1 | 2007 | 312 | 0.020 |
Why?
| Hypothalamus | 1 | 2006 | 150 | 0.020 |
Why?
| Genetics | 1 | 2005 | 28 | 0.020 |
Why?
| Social Support | 1 | 2009 | 541 | 0.020 |
Why?
| Neurosciences | 1 | 2005 | 20 | 0.020 |
Why?
| Models, Theoretical | 1 | 2009 | 527 | 0.020 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2006 | 219 | 0.020 |
Why?
| Clinical Protocols | 1 | 2006 | 233 | 0.020 |
Why?
| Syndecans | 1 | 2004 | 5 | 0.020 |
Why?
| Internet | 1 | 2009 | 596 | 0.020 |
Why?
| Anisotropy | 1 | 2004 | 62 | 0.020 |
Why?
| Antiviral Agents | 1 | 2010 | 648 | 0.010 |
Why?
| Risk Factors | 2 | 2008 | 8714 | 0.010 |
Why?
| Plasma Cells | 1 | 2004 | 57 | 0.010 |
Why?
| Immune System | 1 | 2005 | 173 | 0.010 |
Why?
| Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 2003 | 4 | 0.010 |
Why?
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2003 | 12 | 0.010 |
Why?
| Videotape Recording | 1 | 2003 | 30 | 0.010 |
Why?
| Infrared Rays | 1 | 2003 | 21 | 0.010 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 93 | 0.010 |
Why?
| Meningitis, Viral | 1 | 2003 | 21 | 0.010 |
Why?
| Feasibility Studies | 1 | 2006 | 750 | 0.010 |
Why?
| Saccades | 1 | 2003 | 35 | 0.010 |
Why?
| Antilymphocyte Serum | 1 | 2003 | 66 | 0.010 |
Why?
| Oligoclonal Bands | 1 | 2003 | 21 | 0.010 |
Why?
| Astrocytes | 1 | 2005 | 165 | 0.010 |
Why?
| Mice, Inbred C57BL | 1 | 1992 | 4767 | 0.010 |
Why?
| Antigens, CD34 | 1 | 2003 | 97 | 0.010 |
Why?
| Microglia | 1 | 2005 | 205 | 0.010 |
Why?
| Clone Cells | 1 | 2003 | 247 | 0.010 |
Why?
| Whole-Body Irradiation | 1 | 2003 | 72 | 0.010 |
Why?
| Receptors, Antigen, B-Cell | 1 | 2003 | 102 | 0.010 |
Why?
| Immunoglobulins | 1 | 2003 | 148 | 0.010 |
Why?
| Observer Variation | 1 | 2003 | 299 | 0.010 |
Why?
| Longitudinal Studies | 1 | 2009 | 2437 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2012 | 2408 | 0.010 |
Why?
| Sex Characteristics | 1 | 2007 | 644 | 0.010 |
Why?
| Age Factors | 1 | 2009 | 2915 | 0.010 |
Why?
| Administration, Oral | 1 | 2004 | 731 | 0.010 |
Why?
| Infant | 1 | 2015 | 8002 | 0.010 |
Why?
| Urinary Tract Infections | 1 | 2003 | 136 | 0.010 |
Why?
| Biopsy | 1 | 2005 | 1056 | 0.010 |
Why?
| Cohort Studies | 1 | 2011 | 4961 | 0.010 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 934 | 0.010 |
Why?
| Immunoglobulin kappa-Chains | 1 | 2001 | 18 | 0.010 |
Why?
| Predictive Value of Tests | 1 | 2006 | 1817 | 0.010 |
Why?
| Cytomegalovirus Infections | 1 | 2003 | 180 | 0.010 |
Why?
| Acute Disease | 1 | 2003 | 917 | 0.010 |
Why?
| Immunoglobulin Fab Fragments | 1 | 2001 | 69 | 0.010 |
Why?
| Combined Modality Therapy | 1 | 2003 | 1128 | 0.010 |
Why?
| Research | 1 | 2003 | 398 | 0.010 |
Why?
| Lung | 1 | 1992 | 3685 | 0.010 |
Why?
| Survival Rate | 1 | 2003 | 1653 | 0.010 |
Why?
| Sensitivity and Specificity | 1 | 2003 | 1728 | 0.010 |
Why?
| Arachnoid | 1 | 1998 | 9 | 0.010 |
Why?
| Models, Biological | 1 | 2005 | 1647 | 0.010 |
Why?
| Case-Control Studies | 1 | 2004 | 3056 | 0.010 |
Why?
| Aging | 1 | 2007 | 1641 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2003 | 2814 | 0.010 |
Why?
|
|
Corboy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|